These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19186126)

  • 1. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
    Dixit A; Torkamani A; Schork NJ; Verkhivker G
    Biophys J; 2009 Feb; 96(3):858-74. PubMed ID: 19186126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
    George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
    Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
    Tang Z; Jiang S; Du R; Petri ET; El-Telbany A; Chan PS; Kijima T; Dietrich S; Matsui K; Kobayashi M; Sasada S; Okamoto N; Suzuki H; Kawahara K; Iwasaki T; Nakagawa K; Kawase I; Christensen JG; Hirashima T; Halmos B; Salgia R; Boggon TJ; Kern JA; Ma PC
    Oncogene; 2009 Jan; 28(4):518-33. PubMed ID: 19015641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics study of enhanced autophosphorylation by S904F mutation of the RET kinase domain.
    Chen YJ; Li PY; Yang CN
    J Struct Biol; 2021 Dec; 213(4):107799. PubMed ID: 34563653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
    Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
    Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.
    Dixit A; Verkhivker GM
    PLoS Comput Biol; 2009 Aug; 5(8):e1000487. PubMed ID: 19714203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.
    Cassinelli G; Favini E; Degl'Innocenti D; Salvi A; De Petro G; Pierotti MA; Zunino F; Borrello MG; Lanzi C
    Neoplasia; 2009 Jan; 11(1):10-21. PubMed ID: 19107227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.
    Cao S; Jiang X; Tan C; Fu M; Xiong W; Ji D; Lv J
    J Mol Model; 2021 Nov; 27(11):337. PubMed ID: 34725737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
    Repetto M; Crimini E; Ascione L; Boscolo Bielo L; Belli C; Curigliano G
    Invest New Drugs; 2022 Oct; 40(5):1133-1136. PubMed ID: 35612671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
    Srikakulam SK; Bastys T; Kalinina OV
    Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and chemical inhibition of the RET tyrosine kinase domain.
    Knowles PP; Murray-Rust J; Kjaer S; Scott RP; Hanrahan S; Santoro M; Ibáñez CF; McDonald NQ
    J Biol Chem; 2006 Nov; 281(44):33577-87. PubMed ID: 16928683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
    Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
    PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.
    Miller M; Ginalski K; Lesyng B; Nakaigawa N; Schmidt L; Zbar B
    Proteins; 2001 Jul; 44(1):32-43. PubMed ID: 11354004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
    Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
    Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.
    Cranston AN; Carniti C; Oakhill K; Radzio-Andzelm E; Stone EA; McCallion AS; Hodgson S; Clarke S; Mondellini P; Leyland J; Pierotti MA; Whittaker J; Taylor SS; Bongarzone I; Ponder BA
    Cancer Res; 2006 Oct; 66(20):10179-87. PubMed ID: 17047083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.